Literature DB >> 6265614

Long-term treatment of familial hypophosphatemic rickets with oral phosphate and 1 alpha-hydroxyvitamin D3.

H Rasmussen, M Pechet, C Anast, A Mazur, J Gertner, A E Broadus.   

Abstract

Combined treatment with oral phosphate and 1 alpha (OH)D3 was carried out in nine children with familial hypophosphatemic rickets. All nine had positive responses over a four- to six-year period as judged by healing of rickets, change in growth rate, decrease in alkaline phosphatase activity, and symptomatic improvement. In two patients therapy was stopped for a short time because of hypercalcemia. In one patient in whom therapy was effective there was a significant reduction in creatinine clearance which necessitated cessation of treatment. The results of this study suggest that combined treatment with 1 alpha(OH)D3 and oral phosphate is an effective form of therapy for this condition, but that the balancing of these two modalities of therapy in each patient is essential if hypercalcemia and hypercalciuria, on the one hand, and secondary hyperparathyroidism, on the other, are to be avoided. A simple means of balancing these therapeutic modalities is suggested.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6265614     DOI: 10.1016/s0022-3476(81)80951-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  20 in total

Review 1.  Role of prostaglandins in the pathogenesis of X-linked hypophosphatemia.

Authors:  Michel Baum; Ashu Syal; Raymond Quigley; Mouin Seikaly
Journal:  Pediatr Nephrol       Date:  2006-05-24       Impact factor: 3.714

2.  Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease.

Authors:  Jessica Connor; Elizabeth A Olear; Karl L Insogna; Lee Katz; Suher Baker; Raghbir Kaur; Christine A Simpson; John Sterpka; Robert Dubrow; Jane H Zhang; Thomas O Carpenter
Journal:  J Clin Endocrinol Metab       Date:  2015-07-15       Impact factor: 5.958

3.  Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment.

Authors:  Catherine Quinlan; Katie Guegan; Amaka Offiah; Richard O' Neill; Melanie P Hiorns; Sian Ellard; Detlef Bockenhauer; William Van't Hoff; Aoife M Waters
Journal:  Pediatr Nephrol       Date:  2011-11-20       Impact factor: 3.714

4.  Early treatment of familial hypophosphataemic rickets.

Authors:  M Roza; M A Miguel; M Galbe; L Mejido; C Mencia
Journal:  Arch Dis Child       Date:  1983-12       Impact factor: 3.791

5.  New applications of total parathyroidectomy and autotransplantation: use in proximal renal tubular dysfunction.

Authors:  B K Kinder; H Rasmussen
Journal:  World J Surg       Date:  1985-02       Impact factor: 3.352

6.  Growth hormone therapy in a poorly growing child with hypophosphatemic rickets.

Authors:  R Lanes; H E Harrison
Journal:  J Endocrinol Invest       Date:  1990-11       Impact factor: 4.256

Review 7.  A clinician's guide to X-linked hypophosphatemia.

Authors:  Thomas O Carpenter; Erik A Imel; Ingrid A Holm; Suzanne M Jan de Beur; Karl L Insogna
Journal:  J Bone Miner Res       Date:  2011-05-02       Impact factor: 6.741

Review 8.  Use of calcimimetics in children with normal kidney function.

Authors:  Judith Sebestyen VanSickle; Tarak Srivastava; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2018-03-19       Impact factor: 3.714

9.  Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.

Authors:  R M Harrell; K W Lyles; J M Harrelson; N E Friedman; M K Drezner
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

10.  The pattern of growth and growth retardation of patients with hypophosphataemic vitamin D-resistant rickets: a longitudinal study.

Authors:  R Steendijk; R C Hauspie
Journal:  Eur J Pediatr       Date:  1992-06       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.